A COMPARISON OF SINGLE ORAL AND SINGLE INTRAMUSCULAR DOSE IN THE TREATMENT OF VITAMIN D DEFICIENCY

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202111705598860

Enrollment

106

Registered

2021-11-10

Start date

2021-11-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paediatrics

Interventions

Oral high dose vitamin D.

Intramuscular vitamin D

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All children with suboptimal serum vitamin D3 level (<30ng/dl) and the decision made to treat by the primary physician. 2. Children with suboptimal serum vitamin D3 level with serum levels of parathyroid hormone and calcium. 3. Children aged 3months to 12 years

Exclusion criteria

Exclusion criteria: 1. Children with malabsorption syndromes 2. Children on certain medications which are enzyme inducers e.g. Anti-convulsant, HAART, glucocorticoids, anti-Tuberculosis medications. 3. Children with chronic kidney disease 4. Children with hepatic disorders

Design outcomes

Primary

Measure	Time frame
Serum vitamin D3 levels after three months (ninety days) following administration of a single high oral dose and single high intramuscular dose in children with vitamin D3 deficiency.	—

Secondary

Measure	Time frame
1. To determine the relationship between serum vitamin D3, Parathyroid hormone and calcium levels pre and post treatment with vitamin D3.	—

Countries

Kenya

Contacts

Public ContactWinfred Ndaka

RESIDENT PEDIATRICS

ndakawinnie25@gmail.com+254714732846

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026